TISSIUM logo — Biomorphic Programmable Polymers

TISSIUM

Biomorphic Programmable Polymers

Founded 2013 France France 132 employees Series D Total: $215.20M Biotechnology, Health Care +1

General Information

Company Name TISSIUM
Founded Year 2013
Location France France
Employees 132
Industries Biotechnology, Health Care, Medical Devices
Funding Stage Series D
Social

BounceWatch is an independent company data service, not affiliated with TISSIUM. To contact TISSIUM, visit tissium.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does TISSIUM compare?

A PDF of TISSIUM and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting TISSIUM soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About TISSIUM

TISSIUM is a biotechnology startup with the slogan "Biomorphic Programmable Polymers," initially established in 2013 in France. The company's core objective is to address the persistent medical challenge of tissue reconstruction and restoration of natural function. Their groundbreaking technology, first discovered at the labs of Bob Langer and Jeff Karp at MIT, has the potential to revolutionize tissue reconstruction across various therapeutic areas. TISSIUM's unique product development approach revolves around proprietary polymers, activation technologies, and delivery devices. Moreover, they have established an integrated platform for innovation, design, commercialization, and manufacturing to support internal programs and co-development partnerships with medtech industry leaders. Notably, the company received a significant €50.00M Series D investment on 23 May 2023, with key investors including Sofinnova Partners, Crédit Mutuel Innovation, Mérieux Equity Partners, Cathay Health, and Fonds Stratégique d'Investissement.

Business keywords: Medical Device, MedTech, Synthetic Polymers, Tissue Reconstruction, Biodegradable Sealants, Wound Closure, Minimally Invasive Surgery, Innovation, Research and Development, Biomedical Engineering, Biomedical Materials, Polymer Science, Surgical Adhesives, Biomedical Innovation

Services & Products

development and production of biomorphic programmable polymers for tissue reconstruction

Target Customers

healthcare institutions surgeons medical professionals

Funding Rounds & Investors (11)

View All
Funding Stage Amount Investors Lead Investors Date
Series D €30.00M 5
Mérieux Développement, Cathay +3
24 Jun 2026
Series D €50.00M 5
Sofinnova Partners, Crédit Mutuel Innovation +3
23 May 2023
Series C €50.00M 2
Sofinnova Partners, Cathay Capital
31 Aug 2021
Debt Financing $7.00M 3
Bpifrance, BNP Paribas +1
01 Oct 2020
Venture Round Undisclosed 1
IBD Ventures
11 Feb 2020
Series B €39.00M 8
Bpifrance, Karista +6
20 Nov 2019
Grant €6.00M -
24 Jan 2018
Debt Financing €1.40M 1
Bpifrance
30 Jun 2016
Series A €22.50M 4
Karista, Omnes Capital +2
17 Mar 2016
Venture Round €1.30M 1
Bpifrance
20 Jan 2015

View All 11 Funding Rounds

TISSIUM Alternatives & Competitors

View All Alternatives
TISSIUM vs

Transforming the standard of care in breast cancer surgery.

42 employees
Biotechnology, Health Care
TISSIUM vs

Anchora is developing a unique, single-use automatic suturing device for minimal invasive surgery

Series B
5 employees
Health Care, Medical Devices
TISSIUM vs
AMT Medical
AMT Medical The Netherlands

The future of bypass surgery

Grant
42 employees
Health Care, Medical Devices

FAQ About TISSIUM

Biomorphic Programmable Polymers
TISSIUM was founded in 2013.
TISSIUM is headquartered in France.
TISSIUM operates in Biotechnology, Health Care and Medical Devices. Its work centres on Medical Device, MedTech, Synthetic Polymers and Tissue Reconstruction. Its customers include healthcare institutions, surgeons and medical professionals.
TISSIUM has approximately 132 employees.
TISSIUM has completed 11 funding rounds, raising a total of $215.20M. The latest funding stage is Series D.
TISSIUM offers: development and production of biomorphic programmable polymers for tissue reconstruction.
Top alternatives and competitors to TISSIUM include OncoRes Medical, Anchora Medical Ltd., AMT Medical, Tepha, Inc., Microsure. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
TISSIUM and OncoRes Medical are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for TISSIUM, https://bouncewatch.com/company/tissium, updated 11 June 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes